Does naltrexone block ketamine's antidepressant effect?

In 2018, a Stanford team stopped a trial early. They were giving ketamine to adults with treatment-resistant depression, some of them pretreated with naltrexone, an opioid blocker. In the naltrexone group, the antidepressant effect largely didn’t show up. The dissociation showed up fine in both groups. Only the mood benefit went missing, and the pattern was clear enough that continuing felt unethical to the investigators.

That complicates the tidy story most of us were taught: ketamine as an NMDA-receptor antagonist, mechanism explained. This finding implicates the opioid system in how ketamine lifts mood.

The trial used full-dose naltrexone, the kind prescribed for alcohol or opioid use disorder. Low-dose naltrexone, the 1.5 to 4.5 mg regimen many chronic pain and autoimmune patients take, was not tested. So whether LDN interferes with ketamine is not established. Anyone telling you it definitely does or does not is going past the evidence.

What is established: never advise a patient to stop naltrexone to “make the ketamine work.” Stopping it can restore opioid sensitivity and raise overdose risk in someone with an opioid history. That timing decision belongs to the prescriber and should be made at KAP intake, not discovered mid-series.

I wrote up the trial, its limits, and the intake questions this raises: what the naltrexone finding means for ketamine work.

Peter

P.S. The opioid-system involvement in ketamine is not a footnote when you are assessing misuse risk. Foundations of Ketamine Addiction (2.5 CE) covers the neurobiology, risk factors, and assessment this sits inside.